Aptamers in hematological malignancies and their potential therapeutic implications.
Crit Rev Oncol Hematol
; 106: 108-17, 2016 Oct.
Article
em En
| MEDLINE
| ID: mdl-27637356
Aptamers are short DNA/RNA oligonucleotides selected by the process called Systematic Evolution of Ligands by Exponential Enrichment (SELEX). Due to their functional similarity to monoclonal antibodies with some superior characters, such as high specificity and affinity, flexible modification and stability, and lack of toxicity and immunogenicity, they are promising alternative and complementary targeted therapy for hematologic malignancies. The trends in aptamer technology including production, selection, modifications are briefly discussed in this review. The key aspect is to illustrate aptamers against cancer cells in hematologic malignancies especially those that have entered clinical trials. We also discuss some challenges remain in the application of aptamers.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Hematológicas
/
Aptâmeros de Nucleotídeos
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article